Osteoporosis: Pathophysiology and Epidemiology
Fig. 1.1 Electron micrograph of damaged trabecula . A microcrack is present. Fibrillar structures can be observed spanning the crack as fibrils have been pulled apart from each other. From…
ENDOCRINOLOGY
Factors Contributing to Atypical Femoral Fractures
Fig. 8.1 ASBMR-esta blished AFF criteria and schematic with radiograph illustrating the major features of AFFs The incidence of AFFs is very low [8], especially when compared to the number…
Effects of Antiresorptive Therapy on Bone Microarchitecture
Study Drug Duration (months) N Age (years) Distal radius Tb.vBMD or BV/TV Distal radius Ct.vBMD Distal radius Ct.Th Burghardt et al. (2010) Alendronate 24 13 56 ± 4 NS NS NS Placebo…
Treatment Failure
Year [ref.] Design Subjects Measurements Factors identified Odds ratio/subhazard ratio (95 % CI) 2012 [63] Cross-sectional study 179 postmenopausal women Bone turnover markers DXA Femur structure Fractal analysis Prior fracture…
Conclusions
© Springer International Publishing Switzerland 2016Stuart Silverman and Bo Abrahamsen (eds.)The Duration and Safety of Osteoporosis Treatment10.1007/978-3-319-23639-1_23 23. Conclusions Stuart L. Silverman1 and Bo Abrahamsen2 (1) Division of Rheumatology, Cedars-Sinai Medical Center, UCLA School of Medicine and the…
Integrated Clinical View on Long-Term Management of Patients with Osteoporosis
Medication Short-term issues Long-term issues Comments Estrogena Decreased hot flashes; breast tenderness Venous thromboembolism; stroke Benefit/risk most favorable in younger postmenopausal women; different estrogen preparations may have different clinical profiles…
The Impact of Regulatory and Scientific Organizations’ Recommendations on Clinical Decision-Making
Medication Adverse event Magnitude of association (from pooled analysis of clinical data)a Bisphosphonates Possible association with atypical subtrochanteric fractures of the femur Not available—but the risk for this type of…
Other Safety Concerns
© Springer International Publishing Switzerland 2016Stuart Silverman and Bo Abrahamsen (eds.)The Duration and Safety of Osteoporosis Treatment10.1007/978-3-319-23639-1_20 20. Other Safety Concerns Michael R. McClung1 (1) Oregon Osteoporosis Center, 25 NW 23rd Place, Suite 6 #175, Portland, OR 97210,…
Antiresorptive Therapy, Mortality and Cancer Incidence
Fig. 19.1 Possible interactions between common causes of osteoporosis and fractures and cardiovascular events In the industrialized world, the major causes of death are cardiovascular (including stroke) and cancer. Cancer…
Fractures and Healing on Antiresorptive Therapy
© Springer International Publishing Switzerland 2016Stuart Silverman and Bo Abrahamsen (eds.)The Duration and Safety of Osteoporosis Treatment10.1007/978-3-319-23639-1_18 18. Fractures and Healing on Antiresorptive Therapy Eli Kupperman1 and Susan V. Bukata1 (1) Department of Orthopaedics, UCLA, 1250 16th St.,…
